India’s Pharma Exports Rise 5.21% in Q1 FY26

India’s pharmaceutical exports registered a 5.21% growth in the first quarter of FY26, reaching USD 7.57 billion, according to data from the Pharmaceuticals Export Promotion Council (Pharmexcil). The growth was primarily driven by formulations and biologics, reinforcing India’s position as a key global healthcare supplier. However, challenges such as pricing pressures in the U.S. market continue to weigh on Indian drug manufacturers.

Export Performance

Quarterly Growth

  • Q1 FY26 Exports: USD 7.57 billion
  • Q1 FY25 Exports: USD 7.19 billion (approx.)
  • Growth: +5.21%

The export momentum follows a strong performance in FY25, where India’s pharma exports rose 9.39% to USD 30.47 billion, compared to USD 27.85 billion in FY24.

Key Export Destinations

NAFTA region (North America) remained a primary market.

Growth was also noted in,

  • Oceania
  • Latin America
  • Africa

Despite global expansion, U.S. pricing pressures continue to impact revenues, especially for major generic drug exporters.

Import Trends

  • Rising Imports in Q1 FY26
  • Imports: USD 786 million, up 4.21% from Q1 FY25.

Major Imports

  • Bulk drugs and intermediaries (46% of total imports).
  • Government Push to Reduce Dependency
  • A notable declining trend in bulk drug imports reflects efforts under the Production-Linked Incentive (PLI) scheme, aimed at reducing reliance on foreign intermediaries, especially from China.

Industry Insights

Strengthening Global Role

  • Namit Joshi, Chairman of Pharmexcil, highlighted that Indian pharma continues to solidify its role in the global healthcare ecosystem, supplying affordable and reliable medicines across continents.

Challenges Ahead

  • U.S. market pressures: Intense competition and regulatory pricing curbs affect profitability.
  • Tariff uncertainties: Currently, tariffs on drugs are exempt, but any changes could impact export growth.
  • Sustainability of growth: Industry leaders remain cautiously optimistic, expecting growth but wary of global economic fluctuations.
Shivam

As a Content Executive Writer at Adda247, I am dedicated to helping students stay ahead in their competitive exam preparation by providing clear, engaging, and insightful coverage of both major and minor current affairs. With a keen focus on trends and developments that can be crucial for exams, researches and presents daily news in a way that equips aspirants with the knowledge and confidence they need to excel. Through well-crafted content, Its my duty to ensures that learners remain informed, prepared, and ready to tackle any current affairs-related questions in their exams.

Recent Posts

BRICS 2026: New Delhi Declaration Adopted Unanimously

The BRICS New Delhi Declaration 2026 was signed by all member countries on the first…

18 hours ago

Rameswaram Temple Backdrop Steals Spotlight at BRICS Summit

The renowned Ramanathaswamy Temple located in Rameswaram turned out to be an accidental eye-catcher at…

22 hours ago

Railway Station vs Junction vs Terminal: What Is the Difference?

Station, junction, terminal, and terminus are some terms which are commonly heard on India’s rail…

22 hours ago

Russia Offers India Advanced Engine Upgrade for Su-30MKI

Russia has made another proposal to India on building an advanced fighter engine for upgrading…

23 hours ago

India Crosses 80 Lakh HPV Vaccine Doses in Six Months

India is already at 80 lakh doses of the HPV vaccine within only six months…

23 hours ago

Southern Railway Achieves 100% Electrification Across 5,068 Km

Southern Railway has electrified its entire 5,068 route kilometre broad gauge rail network and made…

24 hours ago